



Print

Submitted

on June 21, 05:40 AM

for ibms2013

Proof

CONTROL ID: 1764694

TITLE: Novel ^{99m}Tc (I)-labeled bone-seeking molecules for bone imaging

AUTHORS (LAST NAME, FIRST NAME): Fernandes, Célia¹; Monteiro, Sofia¹; Mendes, Patricia¹; Gano, Lurdes¹; Marques, Fernanda¹; Casimiro, Sandra²; Costa, Luis^{2, 3}; Santos, Isabel¹

INSTITUTIONS (ALL): 1. Campus Tecnológico e Nuclear, Instituto Superior Técnico, Universidade Técnica de Lisboa, Lisboa, Portugal.

2. Instituto de Medicina Molecular, Lisboa, Portugal.

3. Oncology Department, Hospital de Santa Maria – CHLN, Lisboa, Portugal.

PRESENTATION TYPE: Oral

CURRENT CATEGORY: Other

CURRENT SUB-CATEGORY: None

AWARDS:

ABSTRACT BODY:

Abstract Body: Several malignant tumors, especially breast and prostate cancers, have high tendency to metastasize to bone. Moreover, the development and progression of bone metastases have a high impact in the quality of life of patients, causing drastic complications such as bone pain, pathologic fractures, hypercalcemia and spinal cord compression. Bisphosphonates (BPs) are a class of compounds with high affinity for the bone mineral matrix, binding strongly to the hydroxyapatite (HA) crystals and accumulate in areas of high bone metabolism such as metastases. Consequently, BPs are being extensively explored for the treatment of several bone diseases and as molecular imaging probes. In fact, complexes of ^{99m}Tc with BPs such as methylene diphosphonate (^{99m}Tc -MDP) and hydroxymethylene diphosphonate (^{99m}Tc -HMDP) are widely used as radiopharmaceuticals for the assessment of bone metastases. Despite their proven clinical success these radiopharmaceuticals present several limitations, namely low specificity, uncertainty in the radiopharmaceutical's molecular structure and long acquisition time after injection. Consequently, there is a need for rational design of novel ^{99m}Tc -bisphosphonates based radiopharmaceuticals with improved chemical and biological properties.

Aiming to find novel bone-seeking radiotracers, we have successfully synthesized and characterized a set of novel organometallic compounds of the type $\text{fac-}[\text{M}(\text{CO})_3(\text{k}3\text{-Pz-BP})]$ which contain a bisphosphonate unit (bone seeking agent), and the metal fragment $\text{fac-}[\text{M}(\text{CO})_3]$ ($\text{M} = ^{99m}\text{Tc}$, Re). The stable radioactive complexes were obtained with high yield and radiochemical purity (>95%) and have been characterized by comparing their chromatographic HPLC gamma-traces with the UV-vis traces of the respective Re surrogates. In vitro hydroxyapatite binding studies revealed that the complexes presented bone seeking potential. Herein, we will also present the biodistribution studies in Balb-c mice and compare their biological properties (e.g. bone-targeting properties) with ^{99m}Tc -MDP studied in the same conditions. The best complexes presented fast blood clearance and high bone uptake. Notably, the target to non-target ratios are considerably higher than the ones obtained for ^{99m}Tc -MDP, the gold standard for bone imaging in nuclear medicine.

(No Table Selected)

(No Image Selected)

ScholarOne Abstracts® (patent #7,257,767 and #7,263,655). © ScholarOne, Inc., 2013. All Rights Reserved.
ScholarOne Abstracts and ScholarOne are registered trademarks of ScholarOne, Inc.

 Follow ScholarOne on Twitter

[Terms and Conditions of Use](#)

Product version number 4.2.0 (Build 39)
Build date Jun 19, 2013 15:14:45. Server tss1be0015